ebolavirus
caus
sever
rapidli
progress
hemorrhag
fever
five
ebolaviru
speci
although
much
known
zair
ebolaviru
ebov
neutral
antibodi
littl
known
sudan
ebolaviru
sudv
emerg
increas
frequenc
describ
monoclon
antibodi
contain
human
framework
potent
inhibit
infect
sudv
protect
mice
lethal
challeng
murin
antibodi
bind
sudv
envelop
glycoprotein
gp
serv
start
point
design
sequenc
structur
align
reveal
similar
synthet
antibodi
human
scaffold
focus
phage
librari
construct
screen
impart
recognit
properti
onto
scaffold
panel
antibodi
character
found
rang
neutral
potenti
pseudotyp
viru
infect
model
neutral
correl
gp
bind
determin
elisa
two
clone
potent
inhibit
authent
sudv
confer
protect
memori
immun
mice
lethal
sudv
challeng
shown
bind
epitop
gp
compar
affin
antibodi
repres
strong
immunotherapeut
candid
treatment
sudv
infect
ebolavirus
marburg
viru
marv
compris
famili
filovirida
envelop
negativesens
rna
virus
caus
sever
hemorrhag
fever
base
nucleotid
sequenc
outbreak
locat
isol
ebola
viru
classifi
five
speci
zair
ebov
tai
forest
tafv
sudan
sudv
reston
restv
bundibugyo
bdbv
two
marv
variant
marburg
ravn
sever
human
diseas
ebola
marburg
viral
diseas
associ
ebov
sudv
bdbv
marv
case
fatal
rate
larg
outbreak
ebov
sudv
pathogen
among
ebolavirus
associ
recur
outbreak
among
document
ebov
outbreak
six
sudv
outbreak
averag
human
case
fatal
rate
respect
togeth
ebov
sudv
account
ebola
virusrel
death
statist
includ
ongo
larg
outbreak
west
africa
unpreced
scope
geograph
distribut
mani
studi
direct
understand
ebov
entri
inhibit
viru
entri
antibodi
agent
howev
consider
less
known
marv
sudv
despit
increas
preval
two
speci
current
fdaapprov
therapi
vaccin
treat
filoviru
infect
number
therapeut
strategi
propos
includ
vaccin
small
molecul
modifi
oligonucleotid
passiv
immunotherapi
gain
attent
therapeut
approach
xaxi
posit
number
follow
order
residu
ident
begin
frequent
observ
descend
order
case
four
residu
permit
observ
rest
bin
class
posit
spuriou
addit
mutat
tyr
case
beyond
encod
divers
observ
select
pool
sinc
filovirusspecif
polyclon
igg
cocktail
monoclon
antibodi
mab
provid
postexposur
protect
lethal
challeng
ebov
marv
mice
nonhuman
primat
nhp
envelop
glycoprotein
gp
expect
primari
neutral
target
mab
consist
two
subunit
surfac
subunit
transmembran
subunit
matur
filoviru
gp
spike
trimer
three
disulfidelink
heterodim
gener
produc
cell
endoproteolyt
cleavag
gp
precursor
polypeptid
furin
mediat
viral
adhes
host
cell
regul
activ
transmembran
subunit
mediat
fusion
viral
cellular
membran
cell
entri
prefus
ebov
spike
chaliceandbowl
morpholog
three
subunit
form
chalic
base
spike
three
molecul
form
bowl
sit
atop
chalic
togeth
base
head
subdomain
form
conserv
structur
core
spike
antibodi
bind
neutral
potenti
describ
isol
character
protect
sudvspecif
mab
human
framework
use
synthet
antibodi
approach
number
mab
describ
ebov
character
detail
sudv
one
potent
sudv
mab
murin
antibodi
known
bind
gp
sudv
base
gp
chaliceandbowl
exhibit
potent
neutral
vivo
protect
abil
murin
scaffold
present
potenti
limit
therapeut
use
human
serendipit
observ
high
sequenc
structur
homolog
commonli
use
synthet
human
antibodi
framework
use
structureguid
approach
design
screen
antibodi
librari
would
endow
recognit
properti
onto
human
scaffold
result
antibodi
character
neutral
potenti
abil
confer
vivo
protect
lethal
sudv
challeng
librari
design
select
sequenc
structur
align
murin
scaffold
vascular
endotheli
growth
factor
vegf
specif
synthet
antibodi
human
scaffold
reveal
mark
similar
framework
region
figur
b
amino
acid
level
ident
similar
noncomplementaritydetermin
region
cdr
segment
examin
structur
align
two
antigenbind
fragment
fab
reveal
strong
homolog
framework
segment
lead
cdr
loop
superimpos
framework
two
fab
variabl
domain
fv
exclud
cdr
loop
reveal
rmsd
atom
respect
although
mark
variabl
loop
conform
surmis
appropri
posit
begin
end
cdr
loop
would
allow
product
conform
human
antibodi
contain
cdr
segment
share
framework
mani
synthet
antibodi
deriv
v
h
germlin
segment
favor
characterist
high
express
stabil
mutabl
analysi
suggest
incorpor
recognit
onto
scaffold
might
provid
success
strategi
creat
sudv
antibodi
bear
human
framework
suitabl
immunotherapi
design
construct
human
librari
base
chimer
templat
cdr
segment
graft
onto
scaffold
figur
restrict
diversif
permit
posit
near
cdr
segment
involv
direct
antigen
contact
analog
site
differ
residu
ident
exampl
posit
ile
phe
allow
vari
among
four
residu
pheileleumet
thu
encod
residu
well
two
other
leu
met
similar
properti
random
strategi
appli
sever
posit
well
addit
two
residu
differ
among
tyr
ser
respect
thr
correspond
residu
made
partial
contact
antigen
therefor
two
posit
diversifi
nnk
n
atcg
k
gt
codon
allow
possibl
amino
acid
full
detail
random
strategi
discuss
figur
caption
total
posit
random
theoret
divers
dna
level
protein
level
librari
produc
uniqu
member
allow
exhaust
sampl
librari
express
bival
fab
fusion
piii
gene
previous
describ
synthet
antibodi
bival
display
format
chosen
accur
mimic
natur
igg
would
prefer
downstream
therapeut
format
six
round
select
perform
solubl
recombin
sudv
gp
bonifac
variant
encompass
residu
gp
sudv
protein
includ
major
domain
except
transmembran
domain
ctermin
tail
mostli
trimer
solut
data
shown
previou
work
demonstr
gp
construct
express
mammalian
cell
lack
transmembran
segment
provid
suitabl
mimic
prefus
spike
antibodi
select
bind
structur
studi
sever
hundr
clone
screen
bind
gp
sudv
output
popul
round
monoclon
phage
elisa
identifi
clone
repres
uniqu
sequenc
see
support
inform
distribut
amino
acid
among
clone
repres
figur
compar
requir
recognit
stabil
parallel
select
determin
display
prefer
perform
antiflag
antibodi
flag
epitop
includ
cterminu
phage
display
light
chain
therefor
prefer
display
evid
analysi
comparison
amino
acid
composit
among
elisaposit
clone
function
select
gp
sudv
display
select
distribut
reveal
moder
prefer
gp
sudv
recognit
mani
posit
strong
prefer
residu
posit
heavi
chain
inspect
crystal
structur
suggest
like
support
loop
conform
residu
buri
particip
intern
hydrophob
interact
see
support
inform
residu
particip
structur
paratop
therefor
residu
like
critic
intermolecular
interfac
contrast
residu
ser
posit
less
prefer
compar
cognat
residu
pro
prefer
evid
clone
show
stronger
neutral
efficaci
sinc
pro
strong
effect
loop
conform
pro
posit
may
serv
orient
loop
toward
favor
gp
recognit
human
framework
antibodi
bind
neutral
panel
uniqu
antibodi
produc
molecul
character
preliminari
screen
mab
test
abil
inhibit
infect
vesicular
stomat
viru
pseudotyp
sudv
glycoprotein
vsvgp
sudv
nm
nm
figur
murin
human
ebovspecif
antibodi
includ
posit
neg
control
respect
overal
human
mab
rang
activ
vsvgp
sudv
potent
inhibit
level
onpar
murin
inhibit
nm
nm
notabl
ebovspecif
human
antibodi
activ
even
nm
consist
previou
report
strain
specif
mab
also
test
vsvgp
ebov
activ
nm
thu
human
variant
maintain
specif
profil
murin
parent
orthogon
neutral
activ
human
counterpart
monospecif
sudv
monospecif
ebov
notabl
sinc
independ
cocryst
structur
complex
fabgp
sudv
fabgp
ebov
reveal
antibodi
bind
similar
locat
glycoprotein
fact
structur
epitop
two
fab
overlap
residu
suggest
region
share
neutral
epitop
among
ebolavirus
howev
broadli
neutral
antibodi
bnab
filovirus
yet
describ
point
comparison
bnab
influenza
ha
target
conserv
region
case
compact
structur
epitop
focus
conserv
residu
like
critic
broad
potenc
eleven
clone
exhibit
strong
neutral
potenti
higher
nm
among
favor
express
yield
wellbehav
thu
carri
forward
studi
repres
exampl
dosedepend
inhibit
profil
vsvgp
sudv
reveal
ic
valu
nm
figur
mab
test
authent
sudv
biosafeti
level
condit
found
neutral
ic
nm
nm
figur
sudv
neutral
assay
perform
presenc
guinea
pig
complement
ic
nm
observ
case
result
indic
potent
neutral
activ
sudv
gpmediat
cell
entri
fact
ic
sudv
similar
presenc
absenc
complement
suggest
mechan
involv
bind
gp
inhibit
cell
entri
opson
activ
complement
pathway
perform
competit
elisa
experi
determin
share
common
epitop
biotinyl
capac
unbiotinyl
posit
control
inhibit
bind
dosespecif
manner
evalu
shown
figur
three
unbiotinyl
antibodi
compet
effect
ic
valu
result
indic
three
antibodi
share
epitop
rel
compar
bind
affin
gp
sudv
modestli
reduc
affin
case
sinc
librari
diversif
focus
mostli
support
cdr
loop
residu
rather
direct
contact
site
surpris
affin
human
clone
compar
slightli
decreas
rel
murin
parent
explor
relationship
neutral
potenc
bind
capac
perform
elisa
sever
mab
vari
neutral
potenc
figur
group
strong
neutral
moder
neutral
nonneutr
halfmaxim
bind
titer
ec
correl
strongli
neutral
efficaci
strong
neutral
ec
rang
nm
nm
gp
sudv
moder
neutral
bound
gp
sudv
exhibit
satur
bind
even
micromolar
antibodi
concentr
nonneutr
appreci
bind
activ
notabl
case
bind
activ
observ
specif
gp
sudv
well
contain
neg
control
nonfat
dri
milk
nfdm
mab
also
test
bind
gp
ebov
found
activ
consist
monospecif
neutral
activ
vivo
protect
viral
challeng
antibodi
assess
abil
confer
protect
sudv
challeng
mice
although
mouseadapt
sudv
strain
develop
lethal
immunocompet
mice
humanleth
wildtyp
sudv
viru
use
infect
type
interferon
receptor
knockout
mice
type
r
abil
mab
confer
postexposur
protect
evalu
murin
ebovspecif
mab
ref
includ
control
mice
provid
either
three
dose
day
preexposur
postexposur
figur
b
two
postexposur
dose
day
figur
b
mab
via
intraperiton
rout
challeng
target
dose
plaqu
form
unit
pfu
wildtyp
sudv
day
mice
receiv
sudvspecif
mab
show
similar
level
protect
surviv
figur
wherea
mice
treat
antiebov
specif
mab
show
littl
protect
mice
receiv
one
dose
mab
prior
viral
challeng
threedos
regim
signific
weight
loss
measur
clinic
ill
observ
follow
challeng
mice
receiv
sudvspecif
antibodi
wherea
control
anim
exhibit
signific
weight
loss
maxim
loss
figur
fact
weight
gain
observ
sudvspecif
antibodi
treatment
expect
due
fact
mice
week
old
challeng
still
matur
initi
treatment
mice
delay
day
postexposur
twodos
regim
observ
lethal
sudvspecif
mab
provid
treatment
figur
howev
delay
treatment
observ
definit
weight
loss
antibodytr
mice
absent
day
preexposur
threedos
treatment
scenario
figur
thirtyf
day
follow
initi
challeng
surviv
mice
treat
sudvspecif
antibodi
previous
rechalleng
pfu
wildtyp
sudv
addit
antibodi
treatment
assess
memori
cell
immun
gener
first
exposur
treatment
figur
threedos
group
figur
postexposur
twodos
group
mice
week
old
challeng
unless
otherwis
specifi
surviv
mice
threedos
group
receiv
mab
nonstatist
signific
trend
better
rechalleng
protect
mice
receiv
p
figur
control
demonstr
viru
inject
rechalleng
studi
capabl
induc
morbiditymort
includ
cohort
mice
receiv
antiebov
specif
antibodi
expect
littl
protect
note
treatment
weight
chang
appar
rechalleng
mice
gener
week
old
thu
develop
time
second
infect
figur
surviv
mice
twodos
treatment
rechalleng
week
age
protect
littl
observ
weight
loss
initi
challeng
experi
twodos
postexposur
treatment
group
one
control
mice
surviv
mous
also
surviv
rechalleng
gain
addit
insight
group
untreat
mice
also
includ
rechalleng
experi
figur
sudv
complet
lethal
mice
surviv
anim
show
clinic
sign
diseas
weight
loss
compar
mice
surviv
initi
infect
either
sudv
mab
treatment
without
appar
surviv
mice
memori
immun
show
weight
loss
result
infect
figur
conclus
describ
vitro
vivo
activ
synthet
sudvspecif
antibodi
contain
human
framework
mab
show
potent
neutral
activ
pseudotyp
authent
virus
confer
protect
memori
immun
infect
mice
although
therapeut
antibodymedi
protect
sudv
larger
anim
yet
demonstr
studi
show
ebov
protect
nhp
mani
case
follow
postexposur
treatment
suggest
sudv
antibodi
therapi
explor
mab
report
herein
repres
viabl
candid
antibodi
advantag
favor
serum
halflif
gener
welltoler
especi
contain
human
scaffold
though
compar
bind
studi
strong
modest
poor
neutral
antibodi
elisa
bind
assay
repres
antibodi
strong
modest
poor
neutral
categori
gp
sudv
nfdm
halfmaxim
bind
titer
ec
provid
none
mab
activ
gp
ebov
data
shown
one
fdaapprov
antibodi
antivir
infect
respiratori
syncyti
viru
rsv
number
mab
treatment
consid
variou
viral
diseas
sudv
gp
sequenc
ident
ebov
gp
amino
acid
level
differ
number
structur
function
aspect
sudv
gp
appear
dynam
suscept
proteolyt
degrad
electrostat
neg
surfac
charg
charact
ebov
gp
given
differ
surpris
antibodymedi
neutral
requir
also
differ
exemplifi
fact
bind
similar
overal
posit
prefus
gp
spike
strainspecif
activ
ebov
sudv
report
human
analogu
retain
strain
select
sudv
respons
numer
recent
ebola
viru
outbreak
includ
one
largest
gulu
district
uganda
report
case
death
record
outbreak
develop
sudvspecif
mab
therefor
import
diagnost
research
purpos
well
potenti
immunotherapi
method
phage
display
synthet
gene
templat
construct
human
librari
clone
bival
fab
phagemid
piii
display
templat
consist
dna
encod
chimera
framework
cdr
segment
residu
ident
intend
posit
random
oligonucleotidedirect
mutagenesi
use
incorpor
divers
element
librari
dna
electropor
e
coli
librari
phage
amplifi
accord
standard
protocol
librari
sort
perform
accord
modifi
publish
protocol
recombin
gp
sudv
residu
first
residu
compris
signal
sequenc
remov
matur
express
cell
serv
select
target
purchas
protein
express
laboratori
frederick
nation
laboratori
cancer
research
briefli
gp
sudv
immobil
maxisorp
immunopl
fisher
scientif
nepean
canada
phosphat
buffer
salin
pb
ph
h
well
block
nfdm
h
rt
phage
pool
human
librari
cycl
six
round
bind
select
use
immobil
gp
sudv
captur
target
nfdm
neg
control
stringenc
increas
throughout
select
decreas
number
well
contain
antigen
antigen
load
concentr
progress
round
select
output
phage
popul
round
amplifi
e
coli
cell
broth
supplement
tetracyclin
output
phage
popul
ad
ml
cultur
od
shaken
h
helper
phage
ad
infecti
unit
iu
ml
cultur
shaken
addit
h
ml
cultur
transfer
ml
cultur
broth
supplement
carbenicillin
kanamycin
allow
shake
overnight
h
cell
remov
centrifug
amplifi
phage
precipit
addit
wv
nacl
wv
peg
phage
pellet
figur
protect
mice
three
dose
mab
day
surviv
c
weight
chang
b
curv
initi
challeng
experi
b
rechalleng
surviv
mice
c
weight
chang
data
point
repres
mean
mice
remain
group
given
time
point
rechalleng
experi
old
mice
use
control
group
surviv
curv
statist
signific
differ
control
group
indic
asterisk
p
p
p
p
valu
rechalleng
mice
indic
centrifug
suspend
pb
tween
contain
bsa
pbt
output
popul
screen
bind
use
monoclon
phage
elisa
gp
sudv
immobil
well
well
block
nfdm
describ
sixth
round
select
clone
round
grown
overnight
deep
well
plate
broth
supplement
carbenicillin
helper
phage
iuml
cultur
supernat
appli
directli
elisa
well
contain
antigen
h
rt
identifi
bind
clone
target
gp
sudv
phage
solut
decant
well
wash
time
pb
tween
pbst
score
bind
solut
contain
dilut
peroxidas
hrp
conjug
ge
heathcar
piscataway
nj
ad
allow
bind
min
well
wash
time
pbst
develop
use
substrat
sigmaaldrich
st
loui
mo
elisa
signal
measur
quench
signal
sulfur
acid
determin
absorb
nm
phage
clone
exhibit
phage
elisa
signal
toward
gp
sudv
least
higher
toward
nfdm
subject
dna
sequenc
analysi
express
purif
igg
variabl
domain
dna
phage
clone
amplifi
pcr
digest
subclon
pmazigl
pmazigh
vector
vector
heavi
light
chain
transfect
cell
invitrogen
grand
island
ny
use
linear
polyethylenimin
pei
molecular
weight
da
accord
manufactur
instruct
polysci
warrington
pa
cell
cultur
incub
day
posttransfect
cell
cultur
centrifug
supernat
appli
proteina
affin
column
ml
pack
bead
per
ml
cultur
pierc
thermoscientif
rockford
il
igg
protein
elut
mm
glycin
ph
neutral
tri
ph
eluent
dialyz
pb
ph
igg
protein
concentr
neutral
assay
vsvgp
sudv
vsvgp
ebov
neutral
assay
perform
use
vesicular
stomat
viru
pseudotyp
display
gp
either
sudv
ebov
place
nativ
g
glycoprotein
vsvgp
sudv
vsvgp
ebov
respect
viral
genom
encod
enhanc
green
fluoresc
protein
egfp
infect
score
count
fluoresc
cell
infect
protocol
vsvgp
product
describ
elsewher
briefli
viruscontain
supernat
harvest
concentr
pellet
sucros
cushion
supplement
fb
steril
plate
costarcorn
incorpor
corn
ny
authent
ebov
sudv
dilut
pfuml
ad
well
plate
incub
h
viru
ad
well
contain
media
figur
protect
mice
two
does
mab
day
surviv
c
weight
chang
b
curv
initi
challeng
experi
b
rechalleng
surviv
mice
c
one
control
mous
surviv
initi
challeng
also
surviv
rechalleng
rechalleng
plot
c
data
also
shown
challeng
nineweek
old
mice
complet
succumb
infect
show
sign
ill
form
weight
loss
surviv
curv
statist
signific
differ
control
group
indic
asterisk
p
alon
antibodi
control
infect
cell
expos
virusantibodi
mixtur
incub
addit
h
time
plate
gentli
rock
everi
min
ensur
homogen
prevent
dri
h
incub
ml
primari
overlay
emem
fb
gentamicin
sigmaaldrich
st
loui
mo
seakem
agaros
lonza
cohasset
mn
ad
well
plate
incub
day
day
postexposur
viru
neutral
red
solut
emem
fb
gentamicin
neutral
red
gibcoinvitrogen
grand
island
ny
ad
cellcontain
well
cell
incub
overnight
infect
score
count
number
plaqu
per
well
use
number
plaqu
control
well
antibodi
infect
prnt
assay
complement
perform
use
lowtox
guniea
pig
complement
cedarlan
lyophil
complement
resuspend
ml
icecold
water
dilut
icecold
pb
filter
steril
complement
mixtur
incub
ratio
pfuml
viru
stock
h
gave
final
viral
titer
pfuml
cell
expos
virusantibodycompl
mixtur
h
gentl
rock
everi
min
remain
step
ident
prnt
assay
without
complement
describ
bind
elisa
target
protein
directli
immobil
onto
maxisorp
plate
gp
sudv
gp
ebov
incub
pb
ph
h
pb
ph
contain
nfdm
use
block
well
target
immobil
incub
min
rt
neg
control
plate
coat
nfdm
igg
dilut
pbt
appli
well
incub
rt
h
plate
wash
pbst
incub
min
protein
ahrp
antibodi
conjug
dilut
pbt
well
wash
time
pbst
develop
describ
absorb
nm
determin
data
fit
standard
fourparamet
logist
equat
use
graphpad
prism
graphpad
softwar
la
jolla
ca
halfmaxim
bind
titer
ec
obtain
inflect
point
curv
competit
elisa
perform
previous
describ
biotinyl
use
label
kit
thermo
scientif
rockford
il
accord
manufactur
instruct
gp
sudv
immobil
maxisorp
plate
corn
incorpor
corn
ny
concentr
well
dilut
pbst
buffer
without
vari
amount
three
unbiotinyl
competitor
mixtur
without
competitor
appli
well
incub
rt
h
plate
wash
pbst
horseradish
peroxidasestreptavidin
conjug
dilut
pbst
buffer
ad
incub
min
plate
wash
pbst
develop
tmb
substrat
quench
h
absorb
nm
measur
mous
protect
studi
male
femal
type
ifn
receptor
knockout
mice
type
r
purchas
jackson
laboratori
week
age
util
experi
mice
treat
via
intraperiton
rout
ip
indic
mab
either
day
indic
mab
day
challeng
ip
target
dose
plaqu
form
unit
pfu
wildtyp
sudv
surviv
mice
rechalleng
ip
target
dose
pfu
wildtyp
sudv
treatment
provid
follow
challeng
mice
monitor
daili
morbid
mortal
sequenc
mab
character
neutral
bind
studi
figur
show
potenti
role
combin
site
residu
interact
gp
sudv
materi
avail
free
charg
via
internet
http
pubsacsorg
correspond
author
email
mailmil
email
sachdevsidhu
utorontoca
email
jonlai
einsteinyuedu
